



Stress-related disorders and subsequent risk of life-threatening infections: a population-based sibling-controlled cohort study

Journal:	<i>BMJ</i>
Manuscript ID	BMJ-2019-050247.R1
Article Type:	Research
BMJ Journal:	BMJ
Date Submitted by the Author:	01-Jul-2019
Complete List of Authors:	<p>Song, Huan; University of Iceland; Karolinska Institutet, Medical Epidemiology and biostatistics Fall, Katja; Karolinska Institutet, Dept of Medical Epidemiology and Biostatistic Fang, Fang; Karolinska Institutet, Department of Medical Epidemiology and Biosta Erlendsdóttir, Helga; University of Iceland Lu, Donghao; Karolinska Institutet, Mataix-Cols, David; Karolinska Institutet, Department of Clinical Neuroscience, Center for Psychiatry Research; Institute of Psychiatry, Psychology and Neuroscience. King's College London, Department of Psychosis Studies Fernández de la Cruz, Lorena; Karolinska Institutet, Clinical Neuroscience D'Onofrio, Brian; Indiana University, Department of Psychological and Brain Sciences Lichtenstein, Paul; Karolinska Institutet, Department of Medical Epidemiology Gottfreðsson, Magnús; University of Iceland; Landspítali University Hospital, Department of Infectious Diseases Almqvist, Catarina; Dept of Medical Epidemiology and Biostatistics Valdimarsdttir, Unnur; Centre of Public Health Sciences, University of Iceland, Department of Medicine</p>
Keywords:	Reaction to severe stress, posttraumatic stress disorder, adjustment disorder, life-threatening infections, infection-related death, cohort study

SCHOLARONE™
Manuscripts

1
2
3 **Stress-related disorders and subsequent risk of life-threatening infections: a**
4 **population-based sibling-controlled cohort study**
5
6
7
8

9 Huan Song, postdoctoral fellow^{1,2,3}, Katja Fall, associate professor^{2,4}, Fang Fang, associate professor²,
10 Helga Erlendsdóttir, biomedical scientist^{5,6}, Donghao Lu, postdoctoral fellow², David Mataix-Cols,
11 professor^{7,8}, Lorena Fernández de la Cruz, assistant professor^{7,8}, Brian M D'Onofrio, professor^{2,9}, Paul
12 Lichtenstein, professor², Magnús Gottfreðsson, professor^{5,10}, Catarina Almqvist, professor^{2,11}, Unnur A
13 Valdimarsdóttir, professor^{1,2,12}
14
15
16
17
18

19 1. Center of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavík, Iceland

20 2. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

21 3. West China Biomedical Big Data Center, West China Hospital, Sichuan University, China

22 4. Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro,
23 Sweden

24 5. University of Iceland, Faculty of Medicine, Iceland.

25 6. Department of Clinical Microbiology, Landspítali University Hospital, Iceland.

26 7. Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet,
27 Stockholm, Sweden.

28 8. Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden.

29 9. Department of Psychological and Brain Sciences, Indiana University, Bloomington.

30 10. Department of Infectious Diseases, Landspítali University Hospital, Reykjavík, Iceland.

31 11. Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden

32 12. Department of Epidemiology, Harvard T H Chan School of Public Health, Boston, MA, USA

33 **Correspondence to:** Huan Song, MD, PhD, Center of Public Health Sciences, Faculty of Medicine,
34 University of Iceland, Sturlugata 8, 101 Reykjavík, Iceland (telephone: +354-694 8388; e-mail:
35 huan@hi.is; huan.song@ki.se). ORCID number: 0000-0003-3845-8079.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

58 Word count: Abstract 355

59 Full text 3904
60

1 Abstract

2 **Objective** To assess whether severe psychiatric reactions to trauma and other adversities were associated
3 with subsequent risk of life-threatening infections

4 **Design** Population- and sibling- matched cohort study.

5 **Setting** Swedish population.

6 **Participants** 144,919 patients with stress-related disorders, including posttraumatic stress disorder
7 (PTSD), acute stress reaction, adjustment disorder, and other stress reactions, were identified from 1987
8 to 2013. For comparison, we included 184,612 full siblings of these exposed patients and 1,449,190
9 matched unexposed individuals from general population.

10 **Measurements** Diagnoses of severe infections with high mortality rates (i.e., sepsis, endocarditis,
11 meningitis, and other central nervous system infections) were identified through the Swedish National
12 Patient Register. We also extracted deaths with these infections or infections of any origin from the Cause
13 of Death Register. Controlling for multiple confounders, we used Cox models to estimate hazard ratios of
14 these life-threatening infections.

15 **Results** The average age at diagnosis was 37 years and 38% of exposed patients were male. During a
16 mean follow-up of 8 years, the incidence rate of life-threatening infections was 2.9, 1.7, and 1.3 per 1,000
17 person-years among the exposed, sibling- and matched unexposed- cohorts, respectively. Compared to the
18 unaffected full siblings, patients with stress-related disorders were at increased risk of life-threatening
19 infections (hazard ratios 1.47, 95% confidence intervals 1.37 to 1.58, for any stress related disorder and
20 1.92 (1.46 to 2.52) for PTSD). The corresponding estimates in the population-based analysis were similar
21 (hazard ratios for any stress-related disorder: 1.58, 95% confidence intervals 1.51 to 1.65, *P* for difference
22 between sibling- and population-based comparison=0.09; for PTSD: 1.95 (1.66 to 2.28), *P* for

1
2
3 23 difference=0.92). Stress-related disorders were associated with all studied life-threatening infections, with
4
5 24 the highest magnitude observed for meningitis (sibling-based analysis: hazard ration 1.63 (1.23 to 2.16))
6
7 25 and endocarditis (1.57 (1.08 to 2.30)). Younger age at diagnosis of stress-related disorders and the
8
9 26 presence of psychiatric comorbidity, especially substance use disorders, yielded greater hazard ratios,
10
11 27 while persistent use of selective serotonin reuptake inhibitors throughout the first year after diagnosis of a
12
13 28 stress-related disorder was associated with attenuated hazard ratios.
14
15

16
17 29 **Conclusion** Stress-related disorders are associated with a subsequent increased risk of life-threatening
18
19 30 infections, independent of familial background and physical or psychiatric comorbidities.
20

21
22 31 **Key words** Reaction to severe stress; posttraumatic stress disorder; adjustment disorder; life-threatening
23
24 32 infections; infection-related death; cohort study
25
26

27 33
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

34 **Summary box**

35 **What is already known on this topic**

36 Psychological stress may increase susceptibility to infections through compromised immunity. A series of
37 experimental studies on humans and other animals suggest a link between psychological stress and acute
38 infectious respiratory illness, while data on more severe, life-threatening infections, such as meningitis
39 and sepsis, are limited.

40 **What this study adds**

41 Based on a nationwide population-based sibling-controlled analysis of 144,919 patients diagnosed with
42 stress-related disorders, this is the first study to demonstrate a robust association between stress-related
43 disorders and the subsequent risk of life-threatening infections —including sepsis, endocarditis, central
44 nervous system infections, and fatal infections of any other origin. The association is more pronounced
45 among individuals diagnosed with a stress-related disorder at a younger age, and those with psychiatric
46 comorbidities. The long-term use of selective serotonin reuptake inhibitors was associated with attenuated
47 risk of life-threatening infections after diagnosis of stress-related disorders.

48

49 **Introduction**

50 Excessive or prolonged psychological stress compromises several physiological systems which may
51 increase the individual's susceptibility to disease¹. Strong evidence from animal models² and human
52 studies^{1,3} suggests a considerable modulation of the hypothalamic-pituitary-adrenal axis in response to
53 stress, with altered biological functions such as compromised immunity (e.g., impaired humoral and cell-
54 mediated immunity)¹ and increased inflammatory reactivity¹. Correspondingly, individuals exposed to
55 psychological stress have been reported to have higher risk of respiratory virus infections⁴⁻⁶ paralleled
56 with reduced immune responses to several antiviral/bacterial vaccines⁷⁻¹⁰.

57 Stress-related disorders, including posttraumatic stress disorder (PTSD), acute stress reaction (also
58 known as acute stress disorder), adjustment disorder, and other stress reactions, refer to a group of
59 psychiatric conditions that are preceded and triggered by an identifiable trauma or other life stressors¹¹.
60 With considerable variation in response to adverse events, individuals with stress-related disorders may
61 represent a population with the most severe physiologic dysregulation as a result of severe stress¹.
62 Indeed, populations with PTSD and other stress-related disorders have been reported to have disrupted
63 immune profiles^{1,12-14} and increased risk of various autoimmune diseases¹⁵. Yet, data on major infections
64 in general and life-threatening infections particularly are currently lacking. Therefore, taking advantage of
65 nationwide registers in Sweden, providing complete information on medical diagnoses and family links,
66 we conducted a population-based sibling-controlled cohort study to explore the association between
67 stress-related disorders and subsequent risk of life-threatening infections.

68 **Methods**

69 **Study Design**

70 We first identified all Sweden-born individuals who received their first diagnosis of stress-related
71 disorders between January 1, 1987 and December 31, 2013 (n=156,537; Figure 1) from the Swedish

1
2
3 72 National Patient Register. The National Patient Register has nationwide data from inpatient care since
4
5 73 1987, and specialist outpatient care since 2001. The exposed cohort was then linked to other health
6
7 74 registers in Sweden, utilizing the national identification numbers that are uniquely assigned to all Swedish
8
9 75 residents.

10
11
12 76 We excluded patients diagnosed below age of 5 ($n=139$)¹⁶, with a history of any life-threatening
13
14 77 infection before the diagnosis of the stress-related disorder ($n=4,311$), with conflicting information (died
15
16 78 or emigrated before the diagnosis, $n=24$), or with missing information on county of birth ($n=21$). Further,
17
18 79 to ensure the complete family links from the Swedish Multi-Generation Register¹⁷, we excluded 7,123
19
20 80 patients born before 1932, leaving 144,919 patients for analysis. Patients with stress-related disorders
21
22 81 were considered as ‘exposed’ from the date of their diagnosis (i.e., the index date).

23 24 25 26 82 ***Sibling cohort***

27
28
29 83 To control for familial confounding¹⁶, we constructed a sibling cohort where we compared exposed
30
31 84 patients with their unaffected full siblings. Through the Multi-Generation Register, we identified 184,612
32
33 85 full siblings (of 71.1% [103,072] of all exposed patients) who were free of stress-related disorders and
34
35 86 life-threatening infections at the date of diagnosis of the exposed patient (i.e., the index date).

36 37 38 39 88 ***Population-matched cohort***

40
41
42 89 The comparison of the exposed patients to the general population was performed using a matched cohort
43
44 90 design. We then randomly selected 10 individuals per exposed patient from the Total Population Register
45
46 91 who were free of stress-related disorders and life-threatening infections at the diagnosis date of the
47
48 92 exposed patient. (i.e., the index date). The unexposed individuals were individually matched to the
49
50 93 exposed patient by sex, birth year, and county of birth.

51 52 53 54 94 ***Follow-up***

1
2
3 95 Follow-up of all study participants started from the index date until the occurrence of any or a specific
4
5 96 type of life-threatening infection, death, emigration, or the end of follow-up (December 31, 2013),
6
7 97 whichever occurred first. The follow-up for unaffected full siblings or unexposed individuals was
8
9 98 additionally censored if a diagnosis of stress-related disorder appeared after the index date.

99 ***Stress-related disorders***

100 We defined stress-related disorders as any first inpatient or outpatient visit with the main diagnosis of
101 stress-related disorders registered in the National Patient Register according to the 9th Swedish revisions
102 of the International Classification of Diseases (ICD-9) codes 308, 309 or ICD-10 F43. Stress-related
103 disorders were further divided into PTSD (ICD-9: 309B; ICD-10: F43.1), acute stress reaction (ICD-9:
104 308, 309A; ICD-10: F43.0), and adjustment disorder and other stress reactions (ICD-9: 309X; ICD-10:
105 F43.8, F43.9, details in Supplementary Table 1). Because PTSD might initially be diagnosed as other
106 stress-related disorders (e.g., acute stress reaction¹⁸), we considered all patients receiving a PTSD
107 diagnosis within one year after their first stress-related disorder diagnosis to be PTSD patients.

108 We further obtained information on the dispensation of selective serotonin reuptake inhibitors
109 (Anatomical Therapeutic Chemical code 'N06AB') within the first year after the diagnosis of a stress-
110 related disorder, from the Swedish Prescribed Drug Register (July 2005-). Albeit debates on the
111 appropriateness of use for young patients¹⁹, this medication has been widely used²⁰ and recommended as
112 the first-line pharmacotherapy for adults with stress-related disorders (e.g., in Sweden²¹, UK²², and US²³).
113 We defined users of selective serotonin reuptake inhibitors as patients with two or more dispensations of
114 this drug. We calculated the average dosage by dividing cumulative Defined Daily Dose by the time
115 interval (days) from the first to the last dispensation; and this time interval was also considered as the
116 length of selective serotonin reuptake inhibitors treatment.

117 ***Life-threatening infections***

1
2
3 118 We identified incident cases of severe infections characterized by high fatality (i.e., sepsis, endocarditis,
4
5 119 meningitis, and other central nervous system [CNS] infections), as any first inpatient or outpatient visit
6
7 120 with these infections as the main diagnosis from the National Patient Register, or death with these
8
9 121 infections as the underlying cause of death from the Cause of Death Register. In addition, we identified
10
11 122 all lethal infections of any other origin by identifying deaths with other infections documented as the
12
13 123 underlying cause of death from the Cause of Death Register (Supplementary Table 1).
14
15

16 124 *Covariates*

17
18
19 125 Data on education level, family income, and marital status were obtained from the Longitudinal
20
21 126 Integration Database for Health Insurance and Labor Market study database. Other psychiatric disorders
22
23 127 are commonly diagnosed around the diagnosis of stress-related disorders^{24,25}. Given that co-occurring
24
25 128 psychiatric disorders may also be related to the trauma preceding the diagnosis of stress-related disorder,
26
27 129 and as such represent more severe stress reactions, we considered other psychiatric diagnoses from 3
28
29 130 months before to 1 year after the diagnosis of stress-related disorder as ‘psychiatric comorbidity’. In
30
31 131 contrast, other psychiatric disorders documented more than 3 months before the diagnosis of a stress-
32
33 132 related disorder were considered as ‘history of other psychiatric disorders’. We further obtained
34
35 133 information on history of severe somatic diseases (including myocardial infarction, congestive heart
36
37 134 failure, cerebrovascular disease, chronic pulmonary disease, connective tissue disease, diabetes, renal
38
39 135 diseases, liver diseases, ulcer diseases, and HIV infection/AIDS)²⁶ and history of inpatient visit due to any
40
41 136 infectious disease (as an indicator of baseline susceptibility to infectious diseases). All abovementioned
42
43 137 diagnoses were obtained from the National Patient Register, with corresponding ICD codes shown in
44
45 138 Supplementary Table 1. Family history of major life-threatening infections was defined as any diagnosis
46
47 139 of or death due to sepsis, endocarditis, meningitis, and other CNS infections among biological parents and
48
49 140 full siblings of the study participants, according to the National Patient Register or the Cause of Death
50
51 141 Register. Except for the ‘history of other psychiatric disorder’ and ‘psychiatric comorbidity’, we updated
52
53
54
55

1
2
3 142 information until the index date (i.e., baseline) for all other covariates. For sensitivity analyses on somatic
4
5 143 comorbidities and behavior-related factors, data on the presence of severe somatic diseases (as defined
6
7 144 above) and substance use/sleep-related diseases (Supplemental Table 1) after the index date were also
8
9 145 extracted from the National Patient Register. Anatomic defects (i.e., congenital diseases of heart and
10
11 146 nervous system) are risk factors for severe infections²⁷, and therefore were identified from the National
12
13 147 Patient Register and Medical Birth Register (available from 1973 onwards).

148 **Statistical analysis**

149 We estimated the association between stress-related disorders and risk of life-threatening infections using
150 hazard ratios with 95% confidence intervals, derived from conditional Cox regression models. Time since
151 the index date was applied as the underlying time scale.

152 In the sibling cohort, all models were stratified by family identifier, and adjusting for sex, birth year,
153 education level (<9 years, 9-12 years, >12 years, or unknown), family income (top 20%, middle, lowest
154 20%, or unknown), marital status (single, married or cohabiting, or divorced/widow), history of severe
155 somatic diseases (yes or no), history of other psychiatric disorders (yes or no), and history of inpatient
156 visit due to any infectious diseases (yes or no). We first considered stress-related disorders as one group,
157 and then by diagnostic categories of PTSD, acute stress reaction, and adjustment disorder and other stress
158 reactions. Also, in addition to a diagnosis of any life-threatening infection, we separately examined the
159 risk of sepsis, endocarditis, meningitis, other CNS infections, and deaths due to infections of any other
160 origin.

161 In subgroup analyses, we calculated the hazard ratios by sex (male or female), time since index date
162 (<1 year, 1-5 years, 6-9 years, or ≥ 10 years), calendar period at the index date (1987-2000, 2001-2004, or
163 2005-2013), history of severe somatic diseases (yes or no), family history of major life-threatening
164 infection (yes or no), history of other psychiatric disorders (yes or no), and history of inpatient visit due to
165 any infectious diseases (yes or no). The differences of sub-grouped hazard ratios were assessed by

1
2
3 166 introducing interaction terms to the Cox models or by computing Wald tests. In addition, to examine
4
5 167 potential effect modification by age at index date on the interested association, we applied restricted cubic
6
7 168 splines on age and integrated it to the Cox models by adding an interaction term²⁸. Age-varying hazard
8
9 169 ratios were estimated and visualized thereafter.

11
12 170 To study the potential impact of severity and complexity of stress-related disorder on the studied
13
14 171 associations, we assessed hazard ratios by the presence of psychiatric comorbidity (any psychiatric
15
16 172 comorbidity, as well as by specific type, including depression, anxiety, and substance use disorders) and
17
18 173 by the type of psychiatric care received at diagnosis (inpatient or outpatient). Within one year after the
19
20 174 diagnosis of a stress-related disorder, we considered the psychiatric comorbidity as a time-varying
21
22
23 175 variable.

24
25
26 176 We repeated the main analyses in the population-based cohort, where we used conditional Cox models
27
28 177 stratified by matching identifiers (sex, birth year, and county of birth), adjusting for family history of
29
30 178 major life-threatening infections (yes or no) and all abovementioned covariates. We compared hazard
31
32 179 ratios between sibling and population-based analyses using a z-test²⁹. Further, restricting to exposed
33
34 180 patients diagnosed a stress-related disorder after July 2005 and with more than one-year of follow-up, we
35
36 181 compared the beyond one-year risk of life-threatening infections between subgroups of patients with
37
38 182 different status of selective serotonin reuptake inhibitors use.

39
40
41 183 To test the robustness of the observed associations, we performed several sensitivity analyses. To rule
42
43 184 out the possibility that the observed risk increase was due to a pre-existing or co-occurring medical
44
45 185 condition, we excluded from the analysis individuals with any diagnosis of severe somatic diseases,
46
47 186 injuries and poisonings, or infectious diseases (see codes in Supplemental Table 1) within 1 year prior to
48
49 187 the index date. In addition, to alleviate concerns that the observed associations were accounted for by the
50
51 188 poorer health conditions or suboptimal behaviors of exposed patients than unexposed individuals after the
52
53 189 diagnosis of a stress-related disorder, we restricted our analyses to participants without a history of severe

1
2
3 190 somatic diseases and additionally adjusted the Cox models by the presence of severe somatic conditions
4
5 191 (as time-varying variables), or substance use/sleep related diagnoses (as a binary variable) during follow-
6
7 192 up. Lastly, to address the increased infection risk owing to anatomic defect, we repeated our analyses
8
9 193 after excluding subjects with congenital diseases of heart or nervous system. All analyses were conducted
10
11 194 in SAS statistical software, version 9.4 (Cary, NC) and STATA 15 (StataCorp LP).
12
13

14 195 **Patient and Public Involvement**

16
17 196 No patients were involved in proposing the research question or the outcome measures, nor were they
18
19 197 involved in developing plans for design or implementation of the study. There are no plans to directly
20
21 198 disseminate the results of the research to study participants or the relevant patient community. The
22
23 199 dissemination to the Swedish population (which constitutes the study population) will be achieved
24
25 200 through a media outreach (e.g. press release and communication) upon publication of this study.
26
27
28

29 201 **Results**

30
31
32 202 In total, the sibling cohort accrued 2,370,354 person-years, with an approximately 8-year average
33
34 203 duration of follow-up. The mean age at entry was 37 years (Table 1), and 38.3% of the exposed patients
35
36 204 were male. Prior history of other psychiatric disorders, severe somatic diseases, and inpatient stay due to
37
38 205 infectious diseases were more common among exposed patients than among their full siblings (34.8% vs
39
40 206 12.6%, 16.5% vs 12.8%, and 30.9% vs 23.8%, respectively). In addition, exposed patients tended to have
41
42 207 lower family income and were more likely to be divorced or widowed (Table 1).
43
44
45

46 208 During the follow-up, 4,843 individuals with incident life-threatening infections were identified —2,197
47
48 209 among exposed patients and 2,646 among unaffected full siblings, with a crude incidence rate of 2.7 and
49
50 210 1.7 per 1,000 person-years, respectively. After controlling for all covariates, we observed an association
51
52 211 between stress-related disorders and life-threatening infections: hazard ratios was 1.47 (95% confidence
53
54 212 interval 1.37 to 1.58 for any stress-related disorder, 1.92 (1.46 to 2.52) for PTSD (Figure 2), 1.43 (1.29 to
55
56
57
58
59
60

1
2
3 213 1.58) for acute stress reaction, and 1.48 (1.33 to 1.64) for adjustment disorder and other stress reactions
4
5 214 (Supplementary Figure 1). Stress-related disorders were associated with all studied life-threatening
6
7 215 infections, with hazard ratios varying from 1.39 (1.16 to 1.65) for deaths due to infections of other origin
8
9 216 to 1.63 (1.23 to 2.16) for meningitis. The population-based comparisons corroborated the abovementioned
10
11 217 associations (Figure 2 and Supplementary Figure 1) as differences between the estimates in the sibling-
12
13 218 based and population-based analysis were not statistically significant (hazard ratios for any stress-related
14
15 219 disorder: 1.58 (1.51 to 1.65), P for difference between within-sibling and population-based
16
17 220 comparison=0.09; for PTSD: 1.95 (1.66 to 2.28), P for difference=0.92).

18
19
20
21 221 Based on both sibling and population-based analyses, the observed associations did not differ by sex,
22
23 222 calendar period, family history of life-threatening infections, or history of inpatient stay due to infectious
24
25 223 disease (Table 2 and Supplementary Table 2), but seemed stronger among participants without a history
26
27 224 of severe somatic diseases (P for interaction<.001 in population-based analysis), without history of other
28
29 225 psychiatric disorders (P for interaction<.001 in population-based analysis), and within the first year after
30
31 226 the diagnosis of a stress-related disorder (P for difference<.001 in population-based analysis). Moreover,
32
33 227 an age-dependent risk pattern suggested a linear decline in hazard ratios with increased age at diagnosis
34
35 228 (Figure 3).

36
37
38
39 229 Additionally, we obtained higher hazard ratios for any stress-related disorder diagnosed through
40
41 230 inpatient hospital care, than those from outpatient specialist care (Supplementary Table 3, P for
42
43 231 difference= 0.009 according to population-based analysis). For patients with stress-related disorders other
44
45 232 than PTSD, the presence of psychiatric comorbidity, especially comorbid substance use disorders, was
46
47 233 linked to further elevated relative risk of life-threatening infections in both sibling and population-based
48
49 234 analyses (Supplementary Figure 2).

50
51
52 235 Among exposed patients diagnosed after July 2005 (n=74,691), we found that use of selective
53
54 236 serotonin reuptake inhibitors after the diagnosis of a stress-related disorder was associated with lower

237 beyond one-year risk of life-threatening infections (user compared to non-user: hazard ratio=0.81 (0.66 to
238 0.98), $P=0.032$). Indeed, persistence in use of selective serotonin reuptake inhibitors throughout the first
239 year after a stress-related disorder diagnosis was associated with a linear attenuation in the relative risk of
240 subsequent life-threatening infections (hazard ratio =0.96 (0.66 to 1.40), 0.85 (0.64 to 1.13), and 0.70
241 (0.52 to 0.94) for ≤ 179 , 180-319, and ≥ 320 days of use, respectively, P for trend=0.014; Supplementary
242 Table 4).

243 Restricting the analyses to individuals without any diagnosis of severe somatic diseases, injury, or
244 infectious diseases within 1 year prior to the index date, or individuals without anatomic defects yielded
245 largely identical results as the main analyses (Supplementary Tables 5 and 6). Moreover, while additional
246 adjustments for severe somatic diseases during follow-up did not substantially modify the estimates, the
247 HRs, especially those from the population-based analyses, were attenuated after additionally adjusting for
248 the presence of substance use/sleep-related diagnoses during follow-up (Supplementary Table 7).

249 **Discussion**

250 *Principal findings of the study*

251 To our knowledge, this is the first population-based and sibling-controlled study exploring the association
252 between stress-related disorders and subsequent risk of life-threatening infections. We found that
253 individuals with stress-related disorders, particularly when diagnosed at a young age, were at
254 considerably elevated risk of experiencing life-threatening infections, independently of sex, familial
255 background, and baseline physical or psychiatric conditions. Psychiatric comorbidities, especially
256 substance use disorders, were associated with further risk elevation whilst the long-term (beyond one
257 year) risk of life-threatening infections seemed attenuated by persistent use of selective serotonin reuptake
258 inhibitors during the first year after the diagnosis of a stress-related disorder.

259 *Strengths and weaknesses of this study*

1
2
3 260 The major merit of our study was the use of large population-based cohort with a complete follow-up up
4
5 261 to 27 years and the comparison within full siblings to address the a priori concern for familial
6
7 262 confounding¹⁶. Information bias was minimized because the diagnosis and registration of exposure and
8
9 263 outcome were compiled prospectively and independently. Also, because most of the outcomes of interest
10
11 264 (e.g., sepsis, meningitis) are aggressive diseases, characterized by sudden-onset and severe symptoms, the
12
13 265 influence of surveillance bias or delayed diagnosis should be minor, if any. Furthermore, the large sample
14
15 266 size provided sufficient statistical power for detailed subgroup analyses; and the availability of rich
16
17 267 sociodemographic and medical information enabled considerations of a wide range of important
18
19 268 confounding and mediating factors.

20
21
22
23 269 Notable limitations include: first, the late establishment of Swedish Outpatient Register (2001-)
24
25 270 potentially leads to the underestimated number of stress-related disorder cases, especially the milder
26
27 271 forms. Also, changes in the definition and diagnostic criteria of stress-related disorders over the study
28
29 272 period may have influenced the observed associations. For instance, since 2005, exhaustion disorder has
30
31 273 been introduced into the Swedish ICD-10 system, which results in a small difference between the
32
33 274 Swedish and the international ICD-10 code category 'F43'. However, similar results were obtained from a
34
35 275 sub-analysis of different calendar periods, suggesting a minor influence of these factors. Second, we have
36
37 276 limited information on some important behavior-related factors (e.g., smoking, drug and alcohol use) and
38
39 277 our sensitivity analyses reveal considerable mediating effect of these factors on the observed associations.
40
41 278 Further research with detailed data on lifestyle is warranted. Third, although trauma-focused
42
43 279 psychotherapy was given the highest priority for PTSD treatment in many countries including Sweden²¹,
44
45 280 we have no such data available for analyses. Future well-designed studies exploring the influence of
46
47 281 psychotherapy, alone or with pharmacological treatment, on the association between stress-related
48
49 282 disorder and subsequent risk of severe infections are highly motivated. Fourth, in spite of efforts to
50
51 283 control for disease vulnerabilities (e.g., history of severe somatic diseases, history of other psychiatric
52
53 284 disorders, and history of inpatient visit due to any infectious diseases) that differ between exposed and
54
55

1
2
3 285 reference groups at baseline, we cannot refute the possibility that unmeasured vulnerability factors still
4
5 286 contribute to the reported association. Fifth, this study only involved patients who received a clinical
6
7 287 diagnosis of stress-related disorders through a hospital or specialist visit, thus the generalizability of our
8
9 288 findings to individuals with less severe stress reaction or daily stress needs further assessment.

11 12 289 *Comparison with other studies*

13
14
15 290 With few comparable data, our results reinforce the ‘stress-infection’ link illustrated in previous
16
17 291 experimental studies. Back in the early 1990’s, Dr. Cohen reported a prospective yet non-randomized
18
19 292 study involving 394 healthy volunteers who received viral challenge (nasal drops containing a low dose
20
21 293 of respiratory viruses) after questionnaire-based psychological stress assessment⁴. This study
22
23 294 demonstrated that psychological stress was associated with an increased risk of acute respiratory
24
25 295 infections in a dose-response manner; and similar conclusions were also made in following relevant
26
27 296 research^{5,30,31}. However, since common respiratory viral infections are the predominant disease models in
28
29 297 all aforementioned investigations, it has remained unclear whether the stress-induced immune modulation
30
31 298 can lead to more severe infection-related consequences.

32
33
34
35 299 Consistent with our findings, one recent cohort study³² indicated that a higher perceived stress level was
36
37 300 moderately associated with the 1-year and 10-year risk of sepsis in a sample of 30,183 community-
38
39 301 dwelling adults from US aged 45 years or older. Although suggestive, this study was based on one-time
40
41 302 measurement of psychological stress in an aged population, with limited control of familial- and co-
42
43 303 morbidity factors.

44 45 46 304 *Meaning of the study*

47
48
49 305 With a specific focus on clinically diagnosed stress-related disorders, we show that severe stress
50
51 306 reactions, even in transient form (e.g., acute stress reaction), may increase the subsequent risk of life-
52
53 307 threatening infections, both in the short and long term. Importantly, the observed excess risks seemed

1
2
3 308 relatively independent of most of the known risk factors of the studied infections³³⁻³⁵, such as
4
5 309 socioeconomic factors, familial background, physical conditions at baseline (including baseline
6
7 310 susceptibility to infection), and the occurrence of other severe somatic diseases during the follow-up.
8
9 311 Although relatively rare, severe infections contribute substantially to the global burden of disease due to
10
11 312 high fatality rate, risk of long-term complications, and extremely high health care expense^{36,37}. In contrast,
12
13 313 stress-related disorders are quite common in the general population. The reported lifetime prevalence of
14
15 314 PTSD in Sweden was 5.6% in 2005³⁸, and our data suggest at least 10-times higher prevalence for other
16
17 315 stress-related disorders, underscoring the considerable clinical significance and public health implications
18
19 316 of our findings.
20
21
22

23 317 Initial attempts of explaining the documented 'stress-infection' association were concentrated on altered
24
25 318 circulating glucocorticoids and their role in suppression of cell-mediated and humoral immunity^{39,40},
26
27 319 potentially underlying increased vulnerability to infections among stressed individuals. Yet, studies
28
29 320 testing the association between glucocorticoid levels and risk of infections have yielded mixed results⁴¹⁻⁴⁴.
30
31 321 A recent hypothesis places focus on the underlying inflammation, induced by glucocorticoid receptor
32
33 322 resistance ensuing overproduction of inflammatory cytokines^{6,45}. This notion gains support from several
34
35 323 studies, including the present one, implying that stress experience prior to infections may exacerbate the
36
37 324 severity of infections^{4,46}.
38
39
40

41 325 Alternative explanations for the impact of severe stress reactions on life-threatening infection include
42
43 326 behavior-related changes after the diagnosis of a stress-related disorder. In present study, as we observed
44
45 327 further elevated relative risk among exposed patients with comorbid substance-use disorders, as well as
46
47 328 attenuated excess risk after additionally adjusting for substance use/sleep-related diagnoses during follow-
48
49 329 up, it is therefore possible that behavioral factors (e.g., smoking, alcohol or drug use, and sleep
50
51 330 disturbance) at least partially mediate the observed association, through increased possibility of pathogen
52
53 331 exposure (e.g. needle sharing among drug users⁴⁷) and/or inducing immune dysfunction⁴⁸. Nevertheless, it
54
55
56
57
58
59
60

1
2
3 332 is unlikely that such behavioral factors can fully explain the rise in fatal infection-related consequences,
4
5 333 especially those that appear shortly after a stress-related disorder diagnosis.
6
7

8 334 Our finding suggesting that individuals exposed to stress-related disorders in early life experience the
9
10 335 largest relative risk increase in life-threatening infections is in line with findings showing that childhood
11
12 336 exposure to trauma may have a lifelong impact on susceptibility to disease, through promoting
13
14 337 inflammatory reactions^{49,50}, interrupting neuropsychological/cognitive development^{51,52}, or gene-
15
16 338 environment interplay⁵³. Indeed, the extent of epigenetic modifications, measured as gene-expression
17
18 339 changes, were up to 12 times higher in the childhood trauma-exposed individuals with PTSD compared to
19
20 340 childhood trauma-free PTSD individuals⁵³. These results constitute a molecular basis implying potentially
21
22 341 more extensive biological disruptions, and thereby worse health outcomes for younger, rather than older,
23
24 342 patients with stress-related disorders.
25
26
27

28 343 ***Conclusions***

29
30
31 344 Based on this population-based sibling-controlled cohort study, we found that individuals diagnosed with
32
33 345 stress-related disorders were subsequently at elevated risk of life-threatening infections in the Swedish
34
35 346 population. Despite of its relatively low absolute risk, the high fatality of life-threatening infections calls
36
37 347 for increased clinical awareness among individuals with stress-related disorders, especially those
38
39 348 diagnosed at younger age. In addition, our findings, subject to replication, suggest a potential reduction in
40
41 349 risk of these life-threatening infections with the use of selective serotonin reuptake inhibitors. Further
42
43 350 studies are needed to understand the potential mediating role of behavior-related factors in the observed
44
45 351 association as well as the influence of various treatment modalities for stress-related disorders in reducing
46
47 352 the excess risk of life-threatening infections.
48
49
50

51 353

52
53
54 354

355 **Acknowledgements**

356 We thank Peter Green for contributing his input on readability and accuracy of this document during the
357 review process of the study.

358 **Footnotes**

359 **Contributors:** Study concept and design: HS, UV; data analysis: HS, UV, KF, FF; data interpretation:
360 UV, HS, KF, FF, HE, DL, DMC, LFC, BDO, PL, MG, CA; drafting of the manuscript: HS, UV, KF, FF,
361 HE, DL, DMC, LFC, BDO, PL, MG, CA. HS and UV had full access to all the data in the study and take
362 responsibility for the integrity of the data and the accuracy of the data. HS and UV are guarantors of the
363 article.

364 **Funding:** The study was supported by Grant of Excellence, Icelandic Research Fund (grant no. 163362-
365 051, Dr Valdimarsdóttir), and ERC Consolidator Grant (StressGene, grant no:726413, Dr
366 Valdimarsdóttir); by the Karolinska Institutet (Senior Researcher Award and Strategic Research Area in
367 Epidemiology, Dr Fang); by the Swedish Research Council through the Swedish Initiative for Research
368 on Microdata in the Social And Medical Sciences (SIMSAM) framework (grant no. 340-2013-5867, Dr
369 Almqvist); by the West China Hospital, Sichuan University (1.3.5 Project for Disciplines of Excellence,
370 grant no. ZYJC18010, Dr. Song).

371 **Competing interests:** All authors have completed the ICMJE uniform disclosure form at
372 www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted work;
373 no financial relationships with any organization that might have an interest in the submitted work in the
374 previous three years; no other relationships or activities that could appear to have influenced the
375 submitted work.

376 **Ethical approval:** The study was approved by the Regional Ethics Review Board in Stockholm, Sweden
377 (Dnr. 2013/862-31/5).

378 **Data sharing:** No additional data available.

379 **Transparency:** The study guarantors (HS and UV) affirm that this manuscript is an honest, accurate, and
380 transparent account of the study being reported; that no important aspects of the study have been omitted;
381 and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

382 **Copyright statement:** This is an Open Access article distributed in accordance with the Creative
383 Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute,
384 remix, adapt, build upon this work non-commercially, and license their derivative works on different
385 terms, provided the original work is properly cited and the use is non-commercial. See:
386 <http://creativecommons.org/licenses/by-nc/4.0/>.

387

388 **References**

- 389 1. Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. *Nature*
390 *reviews Immunology* 2005;5(3):243-51.
- 391 2. Curry JM, Hanke ML, Piper MG, et al. Social disruption induces lung inflammation. *Brain Behav Immun*
392 2010;24(3):394-402.
- 393 3. Segerstrom SC, Miller GE. Psychological stress and the human immune system: a meta-analytic study
394 of 30 years of inquiry. *Psychological bulletin* 2004;130(4):601-30.
- 395 4. Cohen S, Tyrrell DAJ, Smith AP. Psychological Stress and Susceptibility to the Common Cold. *New Engl*
396 *J Med* 1991;325(9):606-12.
- 397 5. Cohen S, Doyle WJ, Turner RB, et al. Emotional style and susceptibility to the common cold.
398 *Psychosom Med* 2003;65(4):652-7.
- 399 6. Cohen S, Janicki-Deverts D, Doyle WJ, et al. Chronic stress, glucocorticoid receptor resistance,
400 inflammation, and disease risk. *Proc Natl Acad Sci U S A* 2012;109(16):5995-9.
- 401 7. Pedersen AF, Zachariae R, Bovbjerg DH. Psychological stress and antibody response to influenza
402 vaccination: a meta-analysis. *Brain Behav Immun* 2009;23(4):427-33.
- 403 8. Vedhara K, Cox NK, Wilcock GK, et al. Chronic stress in elderly carers of dementia patients and
404 antibody response to influenza vaccination. *Lancet* 1999;353(9153):627-31.
- 405 9. Glaser R, Kiecolt-Glaser JK, Bonneau RH, et al. Stress-induced modulation of the immune response to
406 recombinant hepatitis B vaccine. *Psychosom Med* 1992;54(1):22-9.

10. Bond E, Lu D, Herweijer E, et al. Sexually transmitted infections after bereavement - a population-based cohort study. *BMC Infect Dis* 2016;16(1):419.
11. (WHO) WHO. The ICD-10 classification of mental and behavioral disorders: Clinical description and diagnostic guidelines (ICD-10). Geneva: World Health Organization 1992.
12. Passos IC, Vasconcelos-Moreno MP, Costa LG, et al. Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression. *Lancet Psychiatry* 2015;2(11):1002-12.
13. Uddin M, Aiello AE, Wildman DE, et al. Epigenetic and immune function profiles associated with posttraumatic stress disorder. *Proc Natl Acad Sci U S A* 2010;107(20):9470-5.
14. Speer K, Upton D, Semple S, et al. Systemic low-grade inflammation in post-traumatic stress disorder: a systematic review. *J Inflamm Res* 2018;11:111-21.
15. Song H, Fang F, Tomasson G, et al. Association of Stress-Related Disorders With Subsequent Autoimmune Disease. *Jama-J Am Med Assoc* 2018;319(23):2388-400.
16. D'Onofrio BM, Lahey BB, Turkheimer E, et al. Critical need for family-based, quasi-experimental designs in integrating genetic and social science research. *Am J Public Health* 2013;103 Suppl 1:S46-55.
17. Ekblom A. The Swedish Multi-generation Register. *Methods Mol Biol* 2011;675:215-20.
18. Harvey AG, Bryant RA. The relationship between acute stress disorder and posttraumatic stress disorder: A 2-year prospective evaluation. *J Consult Clin Psych* 1999;67(6):985-8.
19. Sharma T, Guski LS, Freund N, et al. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. *Brit Med J* 2016;352:i65.
20. Lagerberg T, Molero Y, D'Onofrio BM, et al. Antidepressant prescription patterns and CNS polypharmacy with antidepressants among children, adolescents, and young adults: a population-based study in Sweden. *Eur Child Adolesc Psychiatry* 2019
21. Schafer I, Hopchet M, Vandamme N, et al. Trauma and trauma care in Europe. *Eur J Psychotraumatol* 2018;9(1):1556553.
22. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology. *J Psychopharmacol* 2014;28(5):403-39.
23. Ursano RJ, Bell C, Eth S, et al. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. *The American journal of psychiatry* 2004;161(11 Suppl):3-31.
24. Carta MG, Balestrieri M, Murru A, et al. Adjustment Disorder: epidemiology, diagnosis and treatment. *Clinical practice and epidemiology in mental health : CP & EMH* 2009;5:15.
25. Gros DF, Price M, Magruder KM, et al. Symptom overlap in posttraumatic stress disorder and major depression. *Psychiatry research* 2012;196(2-3):267-70.
26. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *Journal of chronic diseases* 1987;40(5):373-83.
27. Tutarel O, Alonso-Gonzalez R, Montanaro C, et al. Infective endocarditis in adults with congenital heart disease remains a lethal disease. *Heart* 2018;104(2):161-5.
28. FE H. Regression modeling strategies, with applications to linear models, survival analysis and logistic regression. New York, USA: Springer-Verlag, New York, Inc. 2001.
29. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. *Brit Med J* 2003;326(7382):219-.
30. Cohen S, Doyle WJ, Turner R, et al. Sociability and susceptibility to the common cold. *Psychol Sci* 2003;14(5):389-95.

- 1
2
3 454 31. Pedersen A, Zachariae R, Bovbjerg DH. Influence of Psychological Stress on Upper Respiratory
4 455 Infection-A Meta-Analysis of Prospective Studies. *Psychosomatic Medicine* 2010;72(8):823-32.
5 456 32. Ojard C, Donnelly JP, Safford MM, et al. Psychosocial Stress as a Risk Factor for Sepsis: A Population-
6 457 Based Cohort Study. *Psychosomatic Medicine* 2015;77(1):93-100.
7 458 33. van de Beek D, Brouwer M, Hasbun R, et al. Community-acquired bacterial meningitis. *Nat Rev Dis*
8 459 *Primers* 2016;2:16074.
9 460 34. Adriani KS, Brouwer MC, van de Beek D. Risk factors for community-acquired bacterial meningitis in
10 461 adults. *Neth J Med* 2015;73(2):53-60.
11 462 35. Tavare A, O'Flynn N. Recognition, diagnosis, and early management of sepsis: NICE guideline. *Br J*
12 463 *Gen Pract* 2017;67(657):185-6.
13 464 36. Rudd KE, Kissoon N, Limmathurotsakul D, et al. The global burden of sepsis: barriers and potential
14 465 solutions. *Crit Care* 2018;22
15 466 37. Collaborators GBDM. Global, regional, and national burden of meningitis, 1990-2016: a systematic
16 467 analysis for the Global Burden of Disease Study 2016. *Lancet Neurol* 2018;17(12):1061-82.
17 468 38. Frans O, Rimmo PA, Aberg L, et al. Trauma exposure and post-traumatic stress disorder in the
18 469 general population. *Acta Psychiatr Scand* 2005;111(4):291-9.
19 470 39. Bailey M, Engler H, Hunzeker J, et al. The hypothalamic-pituitary-adrenal axis and viral infection.
20 471 *Viral Immunol* 2003;16(2):141-57.
21 472 40. Silverman MN, Pearce BD, Biron CA, et al. Immune modulation of the hypothalamic-pituitary-adrenal
22 473 (HPA) axis during viral infection. *Viral Immunol* 2005;18(1):41-78.
23 474 41. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. *Lancet*
24 475 2003;362(9398):1828-38.
25 476 42. Aucott JN. Glucocorticoids and infection. *Endocrinol Metab Clin North Am* 1994;23(3):655-70.
26 477 43. Janicki-Deverts D, Cohen S, Turner RB, et al. Basal salivary cortisol secretion and susceptibility to
27 478 upper respiratory infection. *Brain Behavior and Immunity* 2016;53:255-61.
28 479 44. Edwards S, Hucklebridge F, Clow A, et al. Components of the diurnal cortisol cycle in relation to
29 480 upper respiratory symptoms and perceived stress. *Psychosomatic Medicine* 2003;65(2):320-7.
30 481 45. Biddie SC, Conway-Campbell BL, Lightman SL. Dynamic regulation of glucocorticoid signalling in
31 482 health and disease. *Rheumatology* 2012;51(3):403-12.
32 483 46. Johnson RR, Prentice TW, Bridegam P, et al. Social stress alters the severity and onset of the chronic
33 484 phase of Theiler's virus infection. *J Neuroimmunol* 2006;175(1-2):39-51.
34 485 47. Mandell W, Vlahov D, Latkin C, et al. Correlates of Needle Sharing among Injection-Drug Users.
35 486 *American Journal of Public Health* 1994;84(6):920-3.
36 487 48. Sopori M. Effects of cigarette smoke on the immune system. *Nature Reviews Immunology*
37 488 2002;2(5):372-7.
38 489 49. Danese A, Caspi A, Williams B, et al. Biological embedding of stress through inflammation processes
39 490 in childhood. *Mol Psychiatry* 2011;16(3):244-6.
40 491 50. Baumeister D, Akhtar R, Ciufofolini S, et al. Childhood trauma and adulthood inflammation: a meta-
41 492 analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor-alpha. *Mol*
42 493 *Psychiatry* 2016;21(5):642-9.
43 494 51. De Bellis MD, Zisk A. The biological effects of childhood trauma. *Child Adolesc Psychiatr Clin N Am*
44 495 2014;23(2):185-222, vii.
45 496 52. Kennedy B, Chen R, Valdimarsdottir U, et al. Childhood Bereavement and Lower Stress Resilience in
46 497 Late Adolescence. *J Adolesc Health* 2018;63(1):108-14.
47 498 53. Mehta D, Klengel T, Conneely KN, et al. Childhood maltreatment is associated with distinct genomic
48 499 and epigenetic profiles in posttraumatic stress disorder. *P Natl Acad Sci USA* 2013;110(20):8302-
49 500 7.

1
2
3 501
4
5

6 502 Figure legends:

7 503

8 504 Figure 1 Study design

9 505

10 506 * Major life-threatening infections of interest include sepsis, endocarditis, meningitis, and other central
11 507 nervous system infections (excl. meningitis).

12 508

13 509 Figure 2 Crude incidence rate (IR) and hazard ratios (HRs) with 95% confidence intervals (CIs) for life-
14 510 threatening infections among patients with any stress-related disorder and posttraumatic stress disorder,
15 511 ***compared to full siblings or matched unexposed individuals***

16 512

17 513 CNS, central nervous system.

18 514 ^a Cox models were stratified by family identifiers, and adjusted for sex, birth year, education level, family
19 515 income, marital status, history of severe somatic diseases, history of other psychiatric disorder, and
20 516 history of inpatient visit due to infectious disease.

21 517

22 518 ^b Cox models were stratified by matching identifiers (sex, birth year, and county of birth), and adjusted
23 519 for education level, family income, marital status, history of severe somatic diseases, history of other
24 520 psychiatric disorder, history of inpatient visit due to infectious disease, and family history of major life-
25 521 threatening infections.

26 522

27 523 Figure 3 The association between stress-related disorder and life-threatening infections by age at the
28 524 index date

29 525

30 526 * Restricted cubic splines were applied on age at index date, with 5 knots placed at 5, 27.5, 50, 72.5, and
31 527 95 quantiles of the distribution of outcome events. Then, age-varying hazard ratios were predicted based
32 528 on fully adjusted Cox models where interaction terms between stress-related disorder and splined age
33 529 profiles were added. In sibling-based analysis, the cox models were stratified by family identifiers, and
34 530 adjusted for sex, birth year, education level, family income, marital status, history of severe somatic
35 531 diseases, history of inpatient visit due to infectious disease, and history of other psychiatric disorder.

36 532

37 533 † In population-based analysis, the cox models were stratified by matching identifiers, i.e., sex, birth year,
38 534 and county of birth, and adjusted for education level, family income, marital status, history of severe
39 535 somatic diseases, history of inpatient visit due to infectious disease, history of other psychiatric disorder,
40 536 and family history of major life-threatening infections

41 537

42 538

43 539

44 540

45 541

46 542

47 543

48 544

49 545

50 546

51 547

52 548

53 549

54 550

55 551

56 552

57 553

58 554

59 555

60 556

539 Table 1 Characteristics of the study cohorts
540

	Sibling cohort		Population-based cohort	
	Exposed cohort	Sibling cohort	Exposed cohort [†]	Matched unexposed cohort
Number of participants	103072	184612	144919	1449190
Age at index date, mean±SD, year	37.0±13.9	38.0±15.1	37.2±14.3	37.2±14.3
Follow-up time, mean±SD, year	7.8±6.4	8.5±6.8	7.9±6.5	8.1±6.6
% of male	38.3%	51.0%	38.3%	38.3%
Education level, n (%)				
<9 years	4191 (4.1)	11919 (6.5)	6453 (4.4)	58565 (4.0)
9-12 years	73505 (71.3)	126305 (68.4)	103252 (71.3)	941393 (65.0)
>12 years	23839 (23.1)	41569 (22.5)	32625 (22.5)	426442 (29.4)
Unknown	1537 (1.5)	4819 (2.6)	2589 (1.8)	22790 (1.6)
Yearly family income level, n (%)				
Lowest 20%	22941 (22.3)	33782 (18.3)	32847 (22.7)	247467 (17.1)
Middle	56877 (55.2)	95927 (52.0)	79051 (54.6)	799409 (55.2)
Top 20%	13160 (12.8)	29946 (16.2)	18292 (12.6)	254009 (17.5)
Unknown	10094 (9.8)	24957 (13.5)	14729 (10.2)	148305 (10.2)
Marital status, n (%)				
Single	58791 (57.0)	100525 (54.5)	82425 (56.9)	823667 (56.8)
Married or cohabiting	30730 (29.8)	66694 (36.1)	42868 (29.6)	514251 (35.5)
Divorced or widowed	13551 (13.2)	17393 (9.4)	19626 (13.5)	111272 (7.7)
History of severe somatic diseases*, n (%)				
Yes	17020 (16.5)	23534 (12.8)	24004 (16.6)	145619 (10.1)
No	86052 (83.5)	161078 (87.3)	120915 (83.4)	1303571 (90.0)
History of other psychiatric disorders[†], n (%)				
Yes	36202 (34.8)	23466 (12.6)	51905 (35.8)	118910 (8.2)
No	67860 (65.2)	162605 (87.4)	93014 (64.2)	1330280 (91.8)
Family history of major life-threatening infections, n (%)				
Yes	10992 (10.7)	20455 (11.1)	15548 (10.7)	134214 (9.3)
No	92080 (89.3)	164157 (88.9)	129371 (89.3)	1314976 (90.7)
History of inpatient visit due to any infectious disease, n (%)				
Yes	31836 (30.9)	43956(23.8)	46269(31.9)	307370(21.2)
No	71236(69.1)	140656(76.2)	98750(68.1)	1141820(78.8)
Type of stress-related disorders, n (%)				
<i>Diagnosis type</i>				
Posttraumatic stress disorder	8105 (7.8)	-	11541 (7.9)	-
Acute stress reaction	47195 (45.8)	-	66758 (46.1)	-
Adjustment disorder and other stress reaction	47772 (46.4)	-	66620 (46.0)	-
<i>Type of psychiatric care received at diagnosis</i>				
Inpatient	37352 (36.2)	-	52817 (36.5)	-
Outpatient	65720 (63.8)	-	92102 (63.5)	-
<i>Psychiatric comorbidity[‡]</i>				
<i>Any</i>				
Yes	22619 (21.9)	-	31415 (21.7)	-
No	80453 (78.1)	-	113504 (78.3)	-
<i>Depression</i>				
Yes	10581(10.3)	-	14500 (10.0)	-
No	92491(89.7)	-	130419 (90.0)	-

<i>Anxiety</i>				
Yes	6683(6.5)	-	9222 (6.4)	-
No	96389(93.5)	-	135697 (93.6)	-
<i>Substance use disorder</i>				
Yes	4567(4.4)	-	6514(4.5)	-
No	98505(95.6)	-	138405 (95.5)	-

541 * Involved somatic diseases included myocardial infarction, congestive heart failure, cerebrovascular disease,
 542 chronic pulmonary disease, connective tissue disease, dementia, diabetes, renal diseases, liver diseases, ulcer
 543 diseases, and HIV infection/AIDS.

544 †The first diagnosis of a psychiatric disorder, other than stress-related disorders, occurred *more than 3* months prior
 545 to the index date (i.e., the diagnosis date of exposed patients, or the diagnosis date of the index patient for matched
 546 unexposed individuals and siblings).

547 ^e A new-onset psychiatric disorder, other than stress-related disorders, diagnosed *from 3* months before *to 1* year
 548 after the diagnosis of a stress-related disorder.

550 Table 2 Hazard ratios (HRs) with 95% confidence intervals (CIs) for life-threatening infections among patients with
 551 any stress-related disorder, **compared to full siblings or matched unexposed individuals**, by different characteristics

	Sibling-based analysis		Population-based analysis	
	Number of cases (IR, per 1 000 person-years), exposed/siblings	HR (95% CI)*	Number of cases (IR, per 1 000 person-years), exposed/unexposed	HR (95% CI)†
By gender				
Male	983(3.11)/1500(1.89)	1.44 (1.26 to 1.64)	1444(3.29)/7034(1.52)	1.57 (1.47 to 1.67)
Female	1214(2.44)/1146(1.48)	1.41 (1.24 to 1.59)	1848(2.66)/8650(1.22)	1.59 (1.50 to 1.68)
By time since index date				
< 1 year	266(2.71)/230(1.30)	1.61 (1.30 to 2.00)	410(2.98)/1438(1.04)	2.04 (1.81 to 2.30)
1-4 years	723(2.34)/805(1.42)	1.53 (1.36 to 1.73)	1045(2.43)/5053(1.16)	1.45 (1.35 to 1.56)
5-9 years	543(2.45)/694(1.64)	1.35 (1.18 to 1.54)	811(2.64)/3941(1.25)	1.51 (1.39 to 1.65)
≥10 years	665(3.59)/917(2.30)	1.50 (1.32 to 1.70)	1026(3.99)/5252(1.88)	1.65 (1.53 to 1.78)
History of severe somatic diseases^e				
Yes	676(5.66)/663(3.92)	1.37 (1.06 to 1.76)	1044(6.09)/3452(3.40)	1.38 (1.23 to 1.56)
No	1521(2.19)/1983(1.42)	1.49 (1.37 to 1.62)	2248(2.34)/12232(1.14)	1.65 (1.57 to 1.73)
By calendar year at index date				
1987-2000	1019(2.82)/1330(1.72)	1.51 (1.37 to 1.67)	1564(3.10)/7401(1.39)	1.66 (1.56 to 1.77)
2001-2005	696(2.52)/833(1.69)	1.31 (1.16 to 1.48)	1035(2.70)/5183(1.34)	1.45 (1.34 to 1.57)
2006-2013	482(2.74)/483(1.60)	1.64 (1.43 to 1.88)	693(2.81)/3100(1.25)	1.60 (1.48 to 1.74)
By previous history of psychiatric disorders[‡]				
Yes	967(4.09)/576(3.86)	1.25 (1.01 to 1.56)	1465(4.33)/2308(3.44)	1.26 (1.12 to 1.41)
No	1230(2.13)/2070(1.46)	1.58 (1.45 to 1.73)	1827(2.30)/13376(1.21)	1.79 (1.70 to 1.88)
By family history of major life-threatening infections				
Yes	219(3.47)/248(1.99)	1.51 (1.20 to 1.89)	300(3.43)/1259(1.64)	1.81 (1.39 to 2.37)
No	1978(2.64)/2398(1.66)	1.38 (1.28 to 1.48)	2992(2.86)/14425(1.32)	1.60 (1.53 to 1.67)
By history of inpatient stay due to infectious disease				
Yes	931(3.94)/812(2.50)	1.25 (1.03 to 1.50)	1405(4.14)/4321(2.04)	1.52 (1.39 to 1.66)
No	1266(2.19)/1834(1.48)	1.58 (1.44 to 1.74)	1887(2.38)/11363(1.19)	1.69 (1.60 to 1.78)

552 *Cox models were stratified by family identifiers, and adjusted for sex, birth year, education level, family income, marital status,
 553 history of severe somatic diseases, history of other psychiatric disorder, and history of inpatient visit due to infectious disease.

554 † Cox models were stratified by matching identifiers (sex, birth year, and county of birth), and adjusted for education level,
 555 family income, marital status, history of severe somatic diseases, history of other psychiatric disorder, history of inpatient visit
 556 due to infectious disease, and family history of major life-threatening infections.

557 ^e Involved somatic diseases included myocardial infarction, congestive heart failure, cerebrovascular disease, chronic pulmonary
 558 disease, connective tissue disease, dementia, diabetes, renal diseases, liver diseases, ulcer diseases, and HIV infection/AIDS.

559 [‡]The first diagnosis of a psychiatric disorder, other than stress-related disorders, occurred more than 3 months prior to the index
 560 date.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Identified from the National Patient
(Inpatient/Outpatient) Register (**main diagnosis**)

156 537 Sweden-born individuals with
new-onset stress-related disorder diagnosed
between 1987-01-01 and 2013-12-31

Excluded subjects


- diagnosed below age of 5, n=139
- had major life-threatening infections* before the onset of stress-related disorder, n= 4 311
- with conflicting information (die or emigrated before diagnosis), n=24
- no information on birth place, n=21
- without available family information from Multi-generation Register (born before 1932), n=7 123

Randomly selected from general population: subjects free of stress-related disorder and free of major life-threatening infections* at the diagnosis date of the index patient (i.e., study entry for unexposed individuals)



1:10 individually matched
(sex, birth year, and county of birth)


- Having trackable full siblings after the diagnosis date of the index patient



Siblings entered the cohort from the diagnosis date of the index patient.


Sibling-based analysis

Population-based analysis



Sibling-based analysis

Population-based analysis



Supplementary Table 1 International Classification of Diseases (ICD) codes for exposure, outcome and covariate identification

Major category	Subgroup	ICD-10 codes	ICD-9 codes (Swedish version)
<u>Stress related disorder</u>			
		F43	308, 309
	Posttraumatic stress disorder	F43.1	309B
	Acute stress reaction	F43.0	308, 309A
	Adjustment disorder	F43.2	309X
	Other specified reactions to severe stress, including exhaustion disorder	F43.8	309X
	Other stress reactions		
	Reactions to severe stress, unspecified	F43.9	309X
<u>Other psychiatric disorders</u>			
	Any other psychiatric disorder	F00-F99 (excl. F43)	209-315 (excl. 308, 309)
	Depression	F32, F33	296B
	Anxiety	F40, F41	300A, 300C
	Substance use disorders	F10-F19	291, 303, 304, 305A, 305X
<u>Major life-threatening infections</u>			
	Sepsis	A02.1, A04.0–A04.3, A39 (excl. A39.0, A39.1, A39.81, A39.9), A40–A41, A42.7, A48, A90–A99, B37.7, B38.7, B39.3, B40.7, B41.7, B42.7, B44.7, B45.7, B46.4, B95–B99	036C–036E, 038, 084, 112F, 117D
	Endocarditis	I33, I38, I39	421, 424X
	Meningitis	A17, A39.0, A39.9, G00–G03	013, 036A, 036X, 320–322
	Other central nervous system infections	A06.6, A39.81, A80–A89, B00.3, B00.4, B01.0, B01.1, B02.0, B02.1, B05.0, B05.1, B06.0, B22.0, B26.1, B26.2, B37.5, B38.4, B43.1, B50.0, B58.2, B60.2, G04–G08	006F, 036B, 045–049, 052B, 053A, 053B, 054D, 054H, 055A, 056A, 062–064, 072B, 072C, 094, 136C, 323–325
<u>Infection-related death (from the Cause of Death Register)</u>			
	Death due to major life-threatening infections	(Sepsis/endocarditis/meningitis/other CNS infections)	See above
	Death due to other infections		See above
	Infection of respiratory tract	Upper respiratory infections and infections of the ear	J00–J06, J32, J35.0, J37.0, J37.1, H60, H65–H67, H70
		Lower respiratory infections	J09–J18, J20–J22, J40–J42
	Sexually transmitted, reproductive, and urinary tract infections		A50–A60, A63.0, A63.8, A64, B20–B24(excl. B22.0), B37.3, B37.4, N10–12, N13.6, N15.1, N15.9, N30, N34.0, N39.0, N41.0–N41.3, N43.1, N45, N48.1, N48.2, N49, N61, N70–N76, N77.1

1				
2				
3	Infections of gastrointestinal tract	Intestinal infections	A00-A09 (excl. A02.1, A04.0–A04.3, A06.6)	001-009 (excl.006F)
4		Hepatitis	B15-B19	070
5		Gastritis and duodenitis	K29	535
6		Appendicitis	K35-K37	540-542
7	Other infections	Skin	A46, L01-L08	035,680-686
8		Eye infections	A54.3, B30, H00.0, H01.0, H04.0, H04.3, H05.0, H05.1, H10, H16, H32	077, 098E, 360A, 360B, 370, 372A-372D, 373, 375A, 376A, 376B
9		Infections of the circulatory system (excl. endocarditis)	I30.0, I30.1, I40.0	420, 422
10		Infections of the musculoskeletal system and connective tissue	M00, M01, M46, M60.0, M65, M71.0, M71.1, M86	711, 727A, 728A, 729E, 730
11		Other bacterial infections	A15-A19, A20-A28, A30-A38, A39 (excl.A39.0, A39.81, A39.9), A42 (excl. A42.7), A43-A45, A47, A49, A65-A69, A70-A79	010-012, 014-018, 020-027,030-034, 035, 036 (excl. 036A,036B, 036X), 037,039-041(excl.040W), 080-083, 100-104
12		Other viral infections	B00-B09 (excl. B00.3, B00.4, B01.0, B01.1, B02.0, B02.1, B05.0, B05.1, B06.0), B25, B26 (excl. B26.1, B26.2), B27-B29,B31-B34	050-059 (excl. 052B, 053A, 053B, 054D, 054H, 055A, 056A), 060, 061, 065, 066, 071-076 (excl. 072B, 072C), 078, 079
13		Other infectious and parasitic diseases	B35, B36, B37(excl. B37.3-B37.5, B37.7), B38 (excl. B38.4, B38.7), B39-B89 (excl. B43.1, B44.7, B45.7, B46.4, B50.0, B58.2, B60.2)	084-088, 110-111,112A,112D,112E,112X, 113-118(excl. 117D), 120-139 (excl.131A, 136C)
14				
15				
16				
17				
18				
19				
20				
21				
22				
23				
24	<u>Covariates: severe somatic conditions</u>			
25				
26	Myocardial infarction		I21, I22, I25.2	410,412
27	Congestive heart failure		I50	428
28	Cerebrovascular disease		G45, G46, I60-I69	430-438
29	Chronic pulmonary disease		J40-J47	490-496
30	Connective tissue disease		M05, M06, M32-M34, M35.1, M35.3	710A, 710B, 710E, 714A, 714B, 714C, 714W,714X, 725
31				
32	Diabetes		E10-E14	250
33	Renal diseases		N01, N03, N05.2-N05.7	582,583
34	Liver diseases		K70.2-K70.4, K71.7, K72.1, K72.9, K73, K74, K76.6, K76.7	571C, 571E,571F, 571G, 572C, 572D, 572E, 572W, 456A, 456B, 456C
35	Ulcer diseases		K25-K28	531-534
36	HIV infection/AIDS		B20-B24 (excl. B22.0)	042-044
37				
38	<u>Covariates: any infectious disease (from National Patient Register)</u>			
39			A00- B99, G00–G08, H10, K29, K35-K37, L01-L08, M00, M01, M46, M60.0, M65, N10-12, N30, N41, N45, J00-J06, J09-J18, J20-J22, J32, J40-J42, I30, I33, I38-I40	001-139, 320–325, 372, 535, 540-542, 680-686, 711, 590, 595, 601, 604, 460-466, 472-474, 480-487, 490, 420-422, 424X
40				
41				
42				
43				
44				
45				
46				
47				

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Covariates: for sensitivity analyses

Injury and poisoning		S00-T98	800-995
	Alcohol use disorder and somatic diseases explicitly linked to alcohol misuse	F10, G31.2, G62.1, I42.6, K29.2, K70, K85.2	291,303,305A, 357F, 425F, 535D, 571A-D
Substance use/sleep-related diagnoses	Tobacco use disorder and somatic diseases highly relevant to tobacco use	F17, J41-J44	305B, 491,492
	Drug use disorder	F11-F16, F18, F19	304
	Sleep disorder	G47, F51, F90	780F,307E

Confidential: For Review Only

Supplementary Table 2 Crude incidence rate (IR) and hazard ratios (HRs) with 95% confidence intervals (CIs) for life-threatening infections among patients with different types of stress-related infections, *compared to matched unexposed individuals*, by different characteristics

	Posttraumatic stress disorder		Acute stress reaction		Adjustment disorder and other stress reactions	
	Number of cases (IR, per 1 000 person-years), exposed/unexposed	HR (95% CI)*	Number of cases (IR, per 1 000 person-years), exposed/unexposed	HR (95% CI)*	Number of cases (IR, per 1 000 person-years), exposed/unexposed	HR (95% CI)*
By gender						
Male	94(3.73)/405(1.54)	2.12 (1.65 to 2.73)	729(3.27)/3537(1.50)	1.55 (1.42 to 1.69)	621(3.25)/3092(1.54)	1.54 (1.40 to 1.70)
Female	150(2.72)/636(1.13)	1.87 (1.53 to 2.29)	841(2.69)/3964(1.24)	1.58 (1.45 to 1.71)	857(2.62)/4050(1.22)	1.56 (1.44 to 1.70)
By time since index date						
< 1 year	25(2.31)/104(0.96)	1.86 (1.12 to 3.10)	213(3.37)/677(1.06)	2.26 (1.91 to 2.68)	172(2.71)/657(1.03)	1.84 (1.53 to 2.22)
1-4 years	71(2.27)/313(1.00)	1.59 (1.19 to 2.13)	479(2.44)/2290(1.15)	1.45 (1.30 to 1.62)	495(2.44)/2450(1.19)	1.45 (1.30 to 1.61)
5-9 years	61(3.08)/206(1.02)	2.42 (1.74 to 3.37)	374(2.60)/1890(1.27)	1.46 (1.29 to 1.65)	376(2.62)/1845(1.25)	1.49 (1.32 to 1.69)
≥10 years	87(4.74)/418(2.11)	2.01 (1.56 to 2.60)	504(3.82)/2644(1.85)	1.57 (1.41 to 1.75)	435(4.07)/2190(1.89)	1.68 (1.49 to 1.88)
History of severe somatic diseases[†]						
Yes	77(6.15)/206(2.95)	1.45 (0.91 to 2.30)	496(6.18)/1642(3.46)	1.37 (1.14 to 1.64)	471(5.99)/1604(3.42)	1.39 (1.16 to 1.66)
No	167(2.46)/835(1.11)	1.86 (1.54 to 2.25)	1074(2.36)/5859(1.15)	1.65 (1.53 to 1.77)	1007(2.29)/5538(1.14)	1.63 (1.51 to 1.75)
By calendar year at index date						
1987-2000	114(3.38)/530(1.48)	2.07 (1.66 to 2.60)	757(3.03)/3624(1.37)	1.63 (1.49 to 1.78)	601(3.05)/2871(1.37)	1.65 (1.49 to 1.82)
2001-2013	130(2.79)/511(1.10)	1.84 (1.48 to 2.29)	813(2.85)/3877(1.34)	1.51 (1.39 to 1.64)	877(2.74)/4271(1.32)	1.51 (1.40 to 1.64)
By previous history of other psychiatric disorders^e						
Yes	105(3.57)/125(2.58)	2.29 (1.47 to 3.56)	729(4.73)/1091(3.50)	1.24 (1.05 to 1.46)	631(4.07)/1092(3.53)	1.17 (0.98 to 1.39)
No	139(2.73)/916(1.18)	2.14 (1.76 to 2.59)	841(2.20)/6410(1.22)	1.70 (1.57 to 1.83)	847(2.34)/6050(1.21)	1.84 (1.70 to 1.98)
By family history of major life-threatening infections						
Yes	20(3.35)/83(1.63)	2.86 (0.88 to 9.31)	144(3.64)/611(1.77)	1.59 (1.06 to 2.38)	136(3.24)/565(1.53)	1.96 (1.33 to 2.89)
No	224(3.01)/958(1.24)	1.93 (1.64 to 2.28)	1426(2.87)/6890(1.32)	1.59 (1.49 to 1.69)	1342(2.82)/6577(1.33)	1.57 (1.47 to 1.68)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

By history of inpatient visit due to infectious disease

Yes	106(4.34)/256(1.73)	2.08 (1.47 to 2.96)	707(4.33)/2026(2.04)	1.69 (1.48 to 1.93)	592(3.90)/2039(2.09)	1.31 (1.14 to 1.50)
No	138(2.47)/785(1.16)	1.81 (1.48 to 2.22)	863(2.32)/5475(1.20)	1.61 (1.49 to 1.74)	886(2.42)/5103(1.17)	1.76 (1.63 to 1.91)

* Cox models were stratified by matching identifiers (sex, birth year, and county of birth), and adjusted for education level, family income, marital status, history of severe somatic diseases, history of other psychiatric disorder, history of inpatient visit due to infectious disease, and family history of major life-threatening infections.
† Involved somatic diseases included myocardial infarction, congestive heart failure, cerebrovascular disease, chronic pulmonary disease, connective tissue disease, dementia, diabetes, renal diseases, liver diseases, ulcer diseases, and HIV infection/AIDS.
‡ The first diagnosis of a psychiatric disorder, other than stress-related disorders, occurred more than 3 months prior to the index date

Confidential: For Review Only

Supplementary Table 3 Relative risks of life-threatening infections among stress-related disorder patients, subgrouped by the type of medical care received at diagnosis, *compared to full siblings or matched unexposed individuals*

	Type of medical care received at diagnosis	Sibling-based analysis		Population-based analysis	
		Number of cases (incidence rate, per 1 000 person-years), exposed/siblings	Hazard ratios (95% confidence intervals)*	Number of cases (incidence rate, per 1 000 person-years), exposed/unexposed	Hazard ratios (95% confidence intervals)†
Any stress-related disorder	Inpatient	1351(2.92)/1648(1.71)	1.52 (1.39 to 1.67)	2065(3.20)/9422(1.39)	1.66 (1.57 to 1.75)
	Outpatient	846(2.41)/998(1.65)	1.39 (1.25 to 1.56)	1227(2.52)/6262(1.28)	1.48 (1.38 to 1.58)
Posttraumatic stress disorder	Inpatient	94(3.20)/109(1.81)	1.81 (1.27 to 2.57)	136(3.36)/591(1.39)	2.15 (1.74 to 2.65)
	Outpatient	76(2.67)/66(1.33)	2.29 (1.44 to 3.65)	108(2.71)/450(1.13)	1.71 (1.35 to 2.18)
Acute stress reaction	Inpatient	682(2.79)/875(1.71)	1.44 (1.27 to 1.64)	1077(3.15)/4970(1.38)	1.60 (1.48 to 1.72)
	Outpatient	331(2.40)/395(1.66)	1.41 (1.18 to 1.69)	493(2.55)/2531(1.30)	1.49 (1.35 to 1.66)
Adjustment disorder and other stress reactions	Inpatient	575(3.04)/664(1.70)	1.57 (1.37 to 1.81)	852(3.23)/3861(1.39)	1.67 (1.53 to 1.82)
	Outpatient	439(2.38)/537(1.69)	1.34 (1.15 to 1.56)	626(2.47)/3281(1.29)	1.44 (1.31 to 1.58)

* Cox models were stratified by family identifiers, and adjusted for sex, birth year, education level, family income, marital status, history of severe somatic diseases, history of other psychiatric disorder, and history of inpatient visit due to infectious disease.

† Cox models were stratified by matching identifiers (sex, birth year, and county of birth), and adjusted for education level, family income, marital status, history of severe somatic diseases, history of other psychiatric disorder, history of inpatient visit due to infectious disease, and family history of major life-threatening infections.

Supplementary Table 4 Relative risks for life-threatening infections among stress-related disorders patients* *with difference status of serotonin selective reuptake inhibitors (SSRI) use*

Information on SSRI use during the first year after a stress-related disorder diagnosis	Number of cases (incidence rate, per 1 000 person-years) among exposed patients	Hazard ratios (95% confidence intervals) [†]
SSRI user[€]		
No	582(2.72)	Reference
Yes	133(2.63)	0.81 (0.66 to 0.98)
<i>P</i> for difference		0.032
Average dosage level of SSRI (by median)		
Not user	582(2.72)	Reference
≤ 1.2 DDD	62(2.32)	0.77 (0.63 to 0.93)
> 1.2 DDD	71(2.98)	0.86 (0.69 to 1.07)
<i>P</i> for trend [‡]		0.090
Duration of SSRI (by tertiles)		
Not user	582(2.72)	Reference
≤179 days	29(3.10)	0.96 (0.66 to 1.40)
180-319 days	54(2.74)	0.85 (0.64 to 1.13)
≥320 days	50(2.33)	0.70 (0.52 to 0.94)
<i>P</i> for trend [‡]		0.014

DDD, Defined Daily Dose

* Restricted to patients diagnosed after July 2005, and with more than one year of follow-up (n=74,691).

[†] Cox models were adjusted for age at index date, sex, county of birth, education level, family income, marital status, history of severe somatic diseases, history of other psychiatric disorder, history of inpatient visit due to infectious disease, family history of major life-threatening infections, and combination use of other psychiatric drugs (yes/no). The first year after the study entry was excluded.

[€] We defined SSRI users as individuals with two or more dispensations of SSRIs within the first year after a stress-related disorder diagnosis.

[‡] *P* for trend was calculated using Wald test.

Supplementary Table 5 Crude incidence rate (IR) and hazard ratios (HRs) with 95% confidence intervals (CIs) for life-threatening infections among patients with stress-related disorder **compared to full siblings or matched unexposed individuals**, restricting to participants without any diagnosis of severe somatic diseases/injury/infectious diseases within 1 year prior to the index date*

	Sibling-based analysis		Population-based analysis	
	Number of cases (IR, per 1 000 person-years), exposed/siblings	HR (95% CI) [†]	Number of cases (IR, per 1 000 person-years), exposed/unexposed	HR (95% CI) [‡]
Any stress-related disorder	1425(2.28)/1617(1.45)	1.52 (1.39 to 1.65)	2146(2.46)/10034(1.19)	1.62 (1.54 to 1.71)
Posttraumatic stress disorder	113(2.64)/106(1.38)	2.10 (1.49 to 2.97)	160(2.67)/666(1.15)	1.91 (1.57 to 2.31)
Acute stress reaction	647(2.24)/755(1.44)	1.46 (1.28 to 1.66)	1016(2.51)/4742(1.20)	1.63 (1.51 to 1.76)
Adjustment disorder and other stress reactions	665(2.27)/756(1.47)	1.52 (1.34 to 1.72)	970(2.39)/4626(1.18)	1.58 (1.47 to 1.71)

* Sample size for analysis in the sibling cohort: 77,746 in exposed group and 126,379 in sibling group; in the population-matched cohort: 110,125 in exposed group and 1,019,447 in unexposed group.

[†] Cox models were stratified by family identifiers, and adjusted for sex, birth year, education level, family income, marital status, history of severe somatic diseases, history of other psychiatric disorder, and history of inpatient visit due to infectious disease.

[‡] Cox models were stratified by matching identifiers (sex, birth year, and county of birth), and adjusted for education level, family income, marital status, history of severe somatic diseases, history of other psychiatric disorder, history of inpatient visit due to infectious disease, and family history of major life-threatening infections.

Supplementary Table 6 Crude incidence rate (IR) and hazard ratios (HRs) with 95% confidence intervals (CIs) for life-threatening infections among patients with stress-related disorder **compared to full siblings or matched unexposed individuals**, restricting to participants without any congenital malformations of heart and nerves system*

	Sibling-based analysis		Population-based analysis	
	Number of cases (IR, per 1 000 person-years), exposed/siblings	HR (95% CI) [†]	Number of cases (IR, per 1 000 person-years), exposed/unexposed	HR (95% CI) [‡]
Any stress-related disorder	1425(2.28)/1617(1.45)	1.52 (1.39 to 1.65)	2146(2.46)/10034(1.19)	1.62 (1.54 to 1.71)
Posttraumatic stress disorder	113(2.64)/106(1.38)	2.10 (1.49 to 2.97)	160(2.67)/666(1.15)	1.91 (1.57 to 2.31)
Acute stress reaction	647(2.24)/755(1.44)	1.46 (1.28 to 1.66)	1016(2.51)/4742(1.20)	1.63 (1.51 to 1.76)
Adjustment disorder and other stress reactions	665(2.27)/756(1.47)	1.52 (1.34 to 1.72)	970(2.39)/4626(1.18)	1.58 (1.47 to 1.71)

* Sample size for analysis in the sibling cohort: 101,314 in exposed group and 179,031 in sibling group; in the population-matched cohort: 142,378 in exposed group and 1,405,627 in unexposed group.

[†] Cox models were stratified by family identifiers, and adjusted for sex, birth year, education level, family income, marital status, history of severe somatic diseases, history of other psychiatric disorder, and history of inpatient visit due to infectious disease.

[‡] Cox models were stratified by matching identifiers (sex, birth year, and county of birth), and adjusted for education level, family income, marital status, history of severe somatic diseases, history of other psychiatric disorder, history of inpatient visit due to infectious disease, and family history of major life-threatening infections.

Supplementary Table 7 Association of stress-related disorders with life-threatening infection, additionally adjusted for the presence of severe somatic diseases (as a time-varying variable) or substance use/sleep-related diagnoses (as a binary variable) during follow-up — analyses restricted to individuals without a history of severe somatic diseases*

	Sibling-based analysis				Population-based analysis			
	Number of cases (incidence rate, per 1 000 person-years), exposed/siblings	HR (95% CI) [†]	HR (95% CI) [†] , additionally adjusted for severe somatic diseases	HR (95% CI) [†] , additionally adjusted for substance use/sleep-related diagnoses	Number of cases (incidence rate, per 1 000 person-years), exposed/unexposed	HR (95% CI) [€]	HR (95% CI) [€] , additionally adjusted for severe somatic diseases	HR (95% CI) [€] , additionally adjusted for substance use/sleep related diagnoses
Any stress-related disorder	1521(2.19)/1613(1.35)	1.49 (1.37 to 1.62)	1.43 (1.30 to 1.56)	1.42 (1.30 to 1.55)	2248(2.34)/9930(1.10)	1.65 (1.57 to 1.73)	1.57 (1.49 to 1.66)	1.50 (1.43 to 1.58)
Posttraumatic stress disorder	115(2.35)/115(1.37)	1.95 (1.40 to 2.73)	1.90 (1.35 to 2.67)	1.83 (1.29 to 2.58)	167(2.46)/682(1.08)	1.86 (1.54 to 2.25)	1.72 (1.42 to 2.09)	1.70 (1.40 to 2.06)
Acute stress reaction	716(2.19)/754(1.32)	1.49 (1.31 to 1.69)	1.41 (1.23 to 1.60)	1.40 (1.23 to 1.60)	1074(2.36)/4741(1.10)	1.65 (1.53 to 1.77)	1.57 (1.45 to 1.69)	1.49 (1.38 to 1.60)
Adjustment disorder and other stress reactions	690(2.17)/744(1.38)	1.45 (1.28 to 1.64)	1.40 (1.23 to 1.59)	1.40 (1.23 to 1.59)	1007(2.29)/4507(1.10)	1.63 (1.51 to 1.75)	1.56 (1.44 to 1.68)	1.49 (1.38 to 1.61)

CI, confidence intervals; HR, Hazard ratios.


* Sample size for analysis in the sibling cohort: 86,052 in exposed group and 136,047 in sibling group; in the population-matched cohort: 120,915 in exposed group and 1,093,047 in unexposed group.

[†] Cox models were stratified by family identifiers, and adjusted for sex, birth year, education level, family income, marital status, history of severe somatic diseases, history of other psychiatric disorder, and history of inpatient visit due to infectious disease.

[€] Cox models were stratified by matching identifiers (sex, birth year, and county of birth), and adjusted for education level, family income, marital status, history of severe somatic diseases, history of other psychiatric disorder, history of inpatient visit due to infectious disease, and family history of major life-threatening infections.

Sibling-based analysis

Population-based analysis



Psychological comorbidity*

Hazard ratio (95% confidence interval)

Sibling-based analysis†

Population-based analysis€

Any psychiatric comorbidity

Any stress-related disorder No
 Yes
 Posttraumatic stress disorder No
 Yes
 Acute stress reaction No
 Yes
 Adjustment disorder and other stress reactions No
 Yes

Comorbid depression


Any stress-related disorder No
 Yes

Comorbid anxiety

Any stress-related disorder No
 Yes

Comorbid substance use disorders

Any stress-related disorder No
 Yes



1
2
3 Supplementary Figure 2 Relative risks of life-threatening infections among stress-related disorder patients, sub-grouped
4 by the occurrence of psychiatric comorbidity, *compared to full siblings or matched unexposed individuals*
5

6 * Psychiatric comorbidity was defined as a new-onset psychiatric disorder, any (excluding stress-related disorder) or specific type (depression,
7 anxiety, and substance use disorders), diagnosed from 3 months before to 1 year after the diagnosis of a stress-related disorder.
8

9 † Cox models were stratified by family identifiers, and adjusted for sex, birth year, education level, family income, marital status, history of severe
10 somatic diseases, history of other psychiatric disorder, and history of inpatient visit due to infectious disease.
11

12 € Cox models were stratified by matching identifiers (sex, birth year, and county of birth), and adjusted for education level, family income, marital
13 status, history of severe somatic diseases, history of other psychiatric disorder, history of inpatient visit due to infectious disease, and family
14 history of major life-threatening infections.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47